Value-based healthcare: Il nuovo approccio di AIFA alla determinazione multidimensionale del valore
- PMID: 36627957
- PMCID: PMC9677615
- DOI: 10.33393/grhta.2020.2102
Value-based healthcare: Il nuovo approccio di AIFA alla determinazione multidimensionale del valore
Abstract
In this viewpoint, we discuss the approach promoted by the Italian Drug Agency (AIFA) to the assessment of the value of new pharmaceuticals in the Italian Healthcare Service. On top of traditionally acknowledged components, such as quality adjusted life years gained and net costs, the overall value framework might include other elements such as productivity and adherence, equity, severity of disease, reduction in uncertainty, spillover effects. There is a residual dimension in the value framework that may capture the option value or reduction in fear of contagion for infectious disease treatments. We debate measurement issues on these elements of value and discuss open issues from a methodological and policy standpoint.
Conflict of interest statement
Conflict of interest: The authors declare no conflict of interest.
Figures
References
-
- Kristensen F. EUnetHTA and health policy-making in Europe. Euro-Health. 2006;12:36–8.
-
- Michael F., Drummond, Mark J., editors. Methods for the economic evaluation of health care programmes. 4th Edition. Sculpher, Karl Claxton, Oxford University Press,; United Kingdom: 2015.
-
- AIFA. Le valutazioni economiche sottomesse ad AIFA nei dossier di richiesta della rimborsabilità e del prezzo (P&R). https://www.aifa.gov.it/documents/20142/1028586/valutazioni_economiche_A...
-
- Sullivan SD, Mauskopf JA, Augustovski F et al. Budget impact analysis—principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health. 2014;17(1):5–14. - PubMed
LinkOut - more resources
Full Text Sources
